AbbVie Inc (ABBV)
171.02
+0.27
(+0.16%)
USD |
NYSE |
Jun 26, 11:04
AbbVie SG&A Expense (Quarterly): 3.315B for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 3.315B |
December 31, 2023 | 3.193B |
September 30, 2023 | 3.372B |
June 30, 2023 | 3.268B |
March 31, 2023 | 3.039B |
December 31, 2022 | 3.417B |
September 30, 2022 | 3.304B |
June 30, 2022 | 5.412B |
March 31, 2022 | 3.127B |
December 31, 2021 | 3.26B |
September 30, 2021 | 3.083B |
June 30, 2021 | 3.164B |
March 31, 2021 | 2.842B |
December 31, 2020 | 3.231B |
September 30, 2020 | 2.846B |
June 30, 2020 | 3.527B |
March 31, 2020 | 1.695B |
December 31, 2019 | 1.951B |
September 30, 2019 | 1.657B |
June 30, 2019 | 1.654B |
March 31, 2019 | 1.68B |
December 31, 2018 | 1.929B |
September 30, 2018 | 1.919B |
June 30, 2018 | 1.76B |
March 31, 2018 | 1.791B |
Date | Value |
---|---|
December 31, 2017 | 1.956B |
September 30, 2017 | 1.457B |
June 30, 2017 | 1.509B |
March 31, 2017 | 1.373B |
December 31, 2016 | 1.679B |
September 30, 2016 | 1.381B |
June 30, 2016 | 1.466B |
March 31, 2016 | 1.355B |
December 31, 2015 | 1.737B |
September 30, 2015 | 1.474B |
June 30, 2015 | 1.703B |
March 31, 2015 | 1.473B |
December 31, 2014 | 3.341B |
September 30, 2014 | 1.595B |
June 30, 2014 | 1.448B |
March 31, 2014 | 1.34B |
December 31, 2013 | 1.448B |
September 30, 2013 | 1.261B |
June 30, 2013 | 1.406B |
March 31, 2013 | 1.237B |
December 31, 2012 | 1.411B |
September 30, 2012 | 1.085B |
June 30, 2012 | 1.246B |
March 31, 2012 | 1.247B |
December 31, 2011 | 1.134B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.654B
Minimum
Jun 2019
5.412B
Maximum
Jun 2022
3.018B
Average
3.178B
Median
SG&A Expense (Quarterly) Benchmarks
Johnson & Johnson | 5.057B |
Eli Lilly and Co | 1.836B |
Pfizer Inc | 3.495B |
Bristol-Myers Squibb Co | 2.367B |
Merck & Co Inc | 2.483B |